Information Provided By: 
Fly News Breaks for June 18, 2018
TROV
Jun 18, 2018 | 07:42 EDT
As reported earlier Maxim analyst Jason McCarthy upgraded Trovagene to Buy from Hold with a price target of $3, citing the positive news from the company's lead drug candidate PCM-075 as well as its completion of a capital raise. The analyst notes that Trovagene's balance sheet now gives it a run rate into the second half of 2019 while the PCM-075 studies progress toward their next set of catalysts. Given the suspension of the financing overhang, McCarthy says the company's potential justifies a more constructive stance.
News For TROV From the Last 2 Days
There are no results for your query TROV
